3-[3-(3-Chloroanilino)-5-methyl-2-sulfanyl-imidazol-4-yl]benzamide | 454464-57-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[3-(3-Chloroanilino)-5-methyl-2-sulfanyl-imidazol-4-yl]benzamide
• 英文别名: 3-[3-(3-chloroanilino)-5-methyl-2-sulfanylidene-1H-imidazol-4-yl]benzamide
• CAS: 454464-57-4
• 化学式: C₁₇H₁₅ClN₄OS
• 分子量: 358.851
• InChiKey: QFFSICWGIQZLJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  103
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-[3-(3-Chloroanilino)-5-methyl-2-sulfanyl-imidazol-4-yl]benzamide 在 双氧水 、 溶剂黄146 作用下， 反应 0.25h， 以84%的产率得到3-[3-(3-Chloroanilino)-5-methyl-imidazol-4-yl]benzamide
  参考文献：
  名称：

  N-Aminoimidazole Derivatives Inhibiting Retroviral Replication via a Yet Unidentified Mode of Action

  摘要：

  The synthesis of a series of N-aminoimidazoles (NAIMs) with an uncommon spectrum of antiretroviral activity is described. From a group of 60 closely related molecules, we were able to subdivide the molecules in different groups based on their anti-HIV and anti-SIV activity in vitro (i) molecules acting on a new, immediate postintegration step, (ii) molecules acting on both postintegration and HIV-1 reverse transcriptase (RT) as NNRTI, and (iii) molecules that mainly act at the HIV-1 RT according to an NNRTI-type mode of action.

  DOI：

  10.1021/jm0211117
• 作为产物：
  描述：

  3-丙酰苯甲腈 在 氢氧化钾 、 硫酸 、 氨 、 溴 、 溶剂黄146 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 50.83h， 生成 3-[3-(3-Chloroanilino)-5-methyl-2-sulfanyl-imidazol-4-yl]benzamide
  参考文献：
  名称：

  N-Aminoimidazole Derivatives Inhibiting Retroviral Replication via a Yet Unidentified Mode of Action

  摘要：

  The synthesis of a series of N-aminoimidazoles (NAIMs) with an uncommon spectrum of antiretroviral activity is described. From a group of 60 closely related molecules, we were able to subdivide the molecules in different groups based on their anti-HIV and anti-SIV activity in vitro (i) molecules acting on a new, immediate postintegration step, (ii) molecules acting on both postintegration and HIV-1 reverse transcriptase (RT) as NNRTI, and (iii) molecules that mainly act at the HIV-1 RT according to an NNRTI-type mode of action.

  DOI：

  10.1021/jm0211117

文献信息

• USE OF N-AMINOIMIDAZOLE CYTOPROTECTIVE COMPOUNDS FOR TREATING CELL DEATH AND/OR GSK-3 MEDIATED DISEASES
  申请人：Pannecouque Christophe

  公开号：US20090149523A1

  公开（公告）日：2009-06-11

  The present invention relates to the use of N-aminoimidazole or N-aminoimidazole-thione derivatives as cytoprotective compounds in vitro and in vivo and for the treatment or prevention of cell death mediated disorders and/or GSK-3 mediated disorders or processes.
• [EN] USE OF N-AMINOIMIDAZOLE CYTOPROTECTIVE COMPOUNDS FOR TREATING CELL DEATH AND/OR GSK-3 MEDIATED DISEASES<br/>[FR] UTILISATION DE COMPOSÉS CYTOPROTECTEURS DE N-AMINOIMIDAZOLE POUR TRAITER DES MALADIES INDUITES PAR LA MORT CELLULAIRE ET/OU PAR GSK-3
  申请人：LEUVEN K U RES & DEV

  公开号：WO2007128088A2

  公开（公告）日：2007-11-15

  [EN] The present invention relates to the use of N-aminoimidazole or N- aminoimidazole-thione derivatives as cytoprotective compounds in vitro and in vivo and for the treatment or prevention of cell death mediated disorders and/or GSK-3 mediated disorders or processes.
  [FR] Cette invention concerne l'utilisation de dérivés de N-aminoimidazole ou de N- aminoimidazole-thione en tant que composés cytoprotecteurs in vitro et in vivo, ainsi que leur utilisation pour traiter ou prévenir des troubles induits par la mort cellulaire et/ou des processus ou des troubles induits par GSK-3.
• <i>N</i>-Aminoimidazole Derivatives Inhibiting Retroviral Replication via a Yet Unidentified Mode of Action
  作者：Irene M. Lagoja、Christophe Pannecouque、Arthur Van Aerschot、Myriam Witvrouw、Zeger Debyser、Jan Balzarini、Piet Herdewijn、Erik De Clercq

  DOI：10.1021/jm0211117

  日期：2003.4.1

  The synthesis of a series of N-aminoimidazoles (NAIMs) with an uncommon spectrum of antiretroviral activity is described. From a group of 60 closely related molecules, we were able to subdivide the molecules in different groups based on their anti-HIV and anti-SIV activity in vitro (i) molecules acting on a new, immediate postintegration step, (ii) molecules acting on both postintegration and HIV-1 reverse transcriptase (RT) as NNRTI, and (iii) molecules that mainly act at the HIV-1 RT according to an NNRTI-type mode of action.